ALKS
HealthcareAlkermes plc · Biotechnology · $6B
What is Alkermes plc?
Alkermes plc is a biopharmaceutical company focused on developing and commercializing treatments for serious conditions including schizophrenia, addiction, and multiple sclerosis. Founded in 1987 and headquartered in Dublin, Ireland, the company operates across the United States, Ireland, and international markets.
Alkermes researches, develops, and sells pharmaceutical products targeting unmet medical needs in psychiatry, addiction medicine, and neurology. The company generates revenue through direct product sales of its marketed portfolio and through collaboration agreements with partners such as Janssen Pharmaceutica. Its pipeline also includes investigational therapies in oncology, reflecting an effort to diversify beyond its established neuroscience franchise.
Alkermes was founded in 1987 and is headquartered in Dublin, Ireland.
- ARISTADA — injectable treatment for schizophrenia
- VIVITROL — treatment for alcohol and opioid dependence
- VUMERITY — oral therapy for relapsing forms of multiple sclerosis
- RISPERDAL CONSTA and INVEGA SUSTENNA — schizophrenia and bipolar disorder treatments
- Nemvaleukin alfa — investigational oncology pipeline asset
Is ALKS a Good Stock to Buy?
UQS Score rates ALKS as Good overall, reflecting a balanced but nuanced profile across its five pillars.
The Risk pillar stands out as a clear strength, suggesting the company carries a relatively conservative financial structure compared to many biopharma peers. The Quality pillar also earns a Good rating, indicating the underlying business generates reasonably dependable results from its commercialized portfolio.
The Moat and Growth pillars both register as Weak, pointing to limited competitive differentiation and constrained near-term expansion prospects — a common challenge for specialty pharma companies reliant on a maturing product mix.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALKS pay dividends?
No — Alkermes plc does not currently pay a dividend.
Alkermes does not currently pay a dividend. For a biopharmaceutical company with an active pipeline and ongoing R&D commitments, retaining capital to fund clinical development and potential pipeline expansion is a common strategic choice. Investors seeking income may need to look elsewhere, while growth-oriented investors may view the reinvestment approach as appropriate given the company's stage.
When does ALKS report earnings?
Alkermes reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's quarterly results typically reflect revenue from its marketed neuroscience products alongside collaboration income from its Janssen partnership. Investors generally watch product revenue trends and pipeline progress as key indicators of business health.
For the most recent quarter's results and guidance, visit Alkermes's investor relations page directly.
ALKS Price History
+47.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alkermes plc?
Based on Alkermes plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ALKS Long-term Outlook
The UQS Growth pillar for ALKS registers as Weak, suggesting the near-term expansion trajectory faces headwinds — a reflection of a mature product portfolio and competitive pressures in specialty psychiatry. The Strong Risk rating, however, indicates the company is positioned to weather uncertainty without excessive financial strain. The Neutral Valuation label implies the market is pricing ALKS neither at a steep premium nor a deep discount relative to fundamentals, leaving the risk-reward profile relatively balanced.
Growth drivers
- Potential label expansion or uptake growth for ARISTADA and VIVITROL in underserved patient populations
- Pipeline progression of nemvaleukin alfa into oncology indications
- Continued collaboration revenue from the Janssen partnership
Key risks
- Weak Moat rating signals limited pricing power and vulnerability to generic or competing therapies
- Weak Growth pillar suggests revenue expansion may remain modest without meaningful pipeline catalysts
- Biopharma regulatory and clinical trial risk could delay or derail pipeline assets
ALKS vs Peers
Alkermes operates in a competitive specialty biopharma landscape alongside companies pursuing neuroscience, oncology, and other therapeutic niches.
Scholar Rock focuses on muscle and metabolic diseases through selective targeting of growth factor signaling, a distinct biological approach from Alkermes's neuroscience and addiction franchise.
TG Therapeutics concentrates on B-cell malignancies and multiple sclerosis, overlapping with Alkermes in the MS space but with a different mechanistic and commercial strategy.
Erasca is a clinical-stage oncology company targeting RAS/MAPK pathway cancers, placing it in a different therapeutic area than Alkermes's core psychiatry and addiction products.
Frequently Asked Questions
What does Alkermes do?
Alkermes is a biopharmaceutical company that develops and sells treatments for serious psychiatric conditions, addiction, and multiple sclerosis. Its marketed products include ARISTADA for schizophrenia, VIVITROL for alcohol and opioid dependence, and VUMERITY for relapsing MS. The company also has an oncology pipeline asset in clinical development.
Does ALKS pay dividends?
Alkermes does not pay a dividend. The company retains capital to fund ongoing research, clinical development, and commercialization activities. Investors focused on income generation may find dividend-paying healthcare companies more suitable for that objective.
When does ALKS report earnings?
Alkermes follows a standard quarterly earnings reporting schedule. Specific dates are announced in advance through the company's investor relations page, which is the most reliable source for upcoming report timing and conference call details.
Is ALKS a good stock to buy?
UQS Score rates ALKS as Good overall. The company shows strength in Risk and Quality pillars, while the Moat and Growth pillars are rated Weak. Whether ALKS fits a particular portfolio depends on individual goals and risk tolerance. The full pillar breakdown is available to UQS Pro members.
Is ALKS overvalued?
The UQS Valuation pillar for ALKS is rated Neutral, suggesting the stock is neither notably expensive nor deeply discounted relative to its fundamentals. This places it in a middle-ground position compared to peers in the specialty biopharma space.
How does ALKS compare to its competitors?
Alkermes competes in specialty biopharma alongside companies like TG Therapeutics, Scholar Rock, and Erasca. Unlike pure clinical-stage peers, Alkermes has an established commercial portfolio generating revenue, which contributes to its relatively stronger Risk and Quality ratings. Detailed comparisons are available on each company's UQS page.
What is ALKS's market cap bracket?
Alkermes is classified as a mid-cap company. This places it between smaller clinical-stage biotechs and large-cap pharmaceutical giants, reflecting its established but not dominant commercial position in specialty neuroscience and addiction medicine.
Who founded Alkermes?
Alkermes was founded in 1987. Detailed founding history, including the names of original founders, is widely available through the company's official corporate history and public filings on its investor relations website.
Is ALKS a long-term quality investment?
From a long-term quality perspective, ALKS earns a Good UQS Score overall. The Strong Risk pillar and Good Quality rating suggest financial stability, but the Weak Moat and Growth pillars indicate the company may face challenges sustaining competitive advantages and expanding revenues over time. Pro members can view the complete analysis.
What is the main competitive advantage of Alkermes?
Alkermes has built expertise in drug formulation technology, particularly long-acting injectable delivery systems used in its psychiatric and addiction products. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company's differentiation may not be durable enough to consistently fend off competition.
What sector does ALKS belong to?
Alkermes operates in the Healthcare sector, specifically within the biopharmaceutical industry. Its focus areas — psychiatry, addiction medicine, and neurology — place it in the specialty pharma segment, which carries distinct regulatory, clinical, and commercial dynamics compared to broader healthcare subsectors.
Unlock Full ALKS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare ALKS against sector peers side by side
- ✓See the complete risk and valuation breakdown
- ✓Track score changes over time with Pro alerts
Pro Analysis
ALKS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 24, 2026 | 39.7 | 47.7 | 39.0 | 33.0 | 37.9 | 38.3 | 0.0 |
| May 20, 2026 | 39.7 | 47.6 | 39.0 | 33.0 | 37.9 | 38.2 | +0.1 |
| May 19, 2026 | 39.6 | 47.5 | 39.0 | 33.0 | 37.9 | 38.1 | 0.0 |
| May 16, 2026 | 39.6 | 47.5 | 39.0 | 33.0 | 37.9 | 38.0 | +0.1 |
| May 15, 2026 | 39.5 | 47.2 | 39.0 | 33.0 | 37.9 | 37.6 | 0.0 |
| May 14, 2026 | 39.5 | 47.2 | 39.0 | 33.0 | 37.9 | 37.4 | -0.2 |
| May 13, 2026 | 39.7 | 47.9 | 39.0 | 33.0 | 37.9 | 37.7 | -0.1 |
| May 12, 2026 | 39.8 | 47.9 | 39.0 | 33.0 | 37.9 | 38.8 | -0.2 |
| May 11, 2026 | 40.0 | 48.0 | 39.0 | 32.9 | 37.9 | 39.7 | -17.8 |
| May 7, 2026 | 57.8 | 73.2 | 39.0 | 32.4 | 100.0 | 55.4 | -0.2 |
ALKS — Pillar Breakdown
Quality
— 47.7/100 (25%)Alkermes plc has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 33.0/100 (20%)Alkermes plc faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 37.9/100 (15%)Alkermes plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 37.7/100 (15%)Alkermes plc has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 39/100 (25%)Alkermes plc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALKS.
Score Composition
Financial Data
More Stock Analysis
How is the ALKS UQS Score Calculated?
The UQS (Unified Quality Score) for Alkermes plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alkermes plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alkermes plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.